Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction.
Roberts
T F
TF
Sprague
K
K
Schenkein
D
D
Miller
K B
KB
Relias
V
V
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000009:adverse effects*; D020520:Brain Infarction / Q000097:blood / Q000139:chemically induced / Q000209:etiology*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy; D007964:Leukocytosis / Q000139:chemically induced* / Q000150:complications; D010087:Oxides / Q000008:administration & dosage / Q000009:adverse effects*; D012008:Recurrence; D012074:Remission Induction / Q000379:methods
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide